Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 308-316

  Hashida, Tohru ^a   Masuda, Satohiro ^a   Uemoto, Shinji ^a   Saito, Hideyuki ^a   Tanaka, Koichi ^a   Inui, Ken ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; JEJUNUM; LIVER TRANSPLANTATION; LIVING DONOR; MICROPARTICLE ENZYME IMMUNOASSAY; MULTIDRUG RESISTANCE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE;

ADOLESCENT; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENES, MDR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTESTINES; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 0035336558     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115142     Document Type: Article

References (27)

1. Broelsch CE, Whitington PF, Emond JC, Heffron TG, Thistlethwaite JR, Stevens L, et al. Liver transplantation in children from living related donors: Surgical techniques and results. Ann Surg 1991;214:428-37.
2. de Ville de Goyet J, Hausleithner V, Reding R, Lerut J, Janssen M, Otte JB. Impact of innovative techniques on the waiting list and results in pediatric liver transplantation. Transplantation 1993;56:1130-6.
3. Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, Yamamoto E, et al. Living related liver transplantation in children. Am J Surg 1994;168:41-8.
4. Kiuchi T, Inomata Y, Uemoto S, Asonuma K, Egawa H, Hayashi M, et al. Living-donor liver transplantation in Kyoto, 1997. Clin Transpl 1997;18:191-8.
5. Inomata Y, Kiuchi T, Kim I, Uemoto S, Egawa H, AsonUma K, et al. Auxiliary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients. Transplantation 1999;67:1314-9.
6. Inomata Y, Uemoto S, Asonuma K, Egawa H, Kiuchi T, Fujita S, et al. Right lobe graft in living donor liver transplantation. Transplantation 2000;69:258-64.
7. Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998;30:2174-8.
8. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999;230:441-8.
9. Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995;27:1108-10.
10. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-90.
11. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
12. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000;68:98-103.
13. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: Possible relationship to intestinal P-glycoprotein activity. Transplantation 1999;67:333-5.
14. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24.
15. Christians U, Bleck JS, Lampen A, Bader A, Thiesemann C, Kliem V, et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996;28:2159-61.
16. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60: 14-24.
17. Floren LC, Bekersky I, Benet LZ, Mekki Q, DRessler D, Lee JW, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
18. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999;27: 161-6.
19. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
20. Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, Nishizawa T, et al. Surgical techniques and innovations in living related liver transplantation. Ann Surg 1993; 217:82-91.
21. Masuda S, Saito H, Nonoguchi H, Tomita K, Inui K. MRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Lett 1997;407:127-31.
22. Tanaka K, Hirai M, Tanigawara Y, Ueda K, Takano M, Hori R, et al. Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene. Biochem Pharmacol 1997;53:741-6.
23. Inomata Y, Tanaka K, Egawa H, Uemoto S, Ozaki N, Okajima H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996;61:247-52.
24. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, MOrrison M, Blonski D, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991;23: 2748-9.
25. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin RP, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-60.
26. Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999;67:321-7.
27. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.